使用ExacTell技术对与HPV有关的先发性宫颈损伤进行TVGN 920电子生物先进细胞治疗。 Tevogen Bio advances cell therapy TVGN 920 for HPV-associated precancerous cervical lesions using ExacTcell technology.

Tevogen Bio正在利用其调查产品TVGN 920,推进细胞疗法,以治疗与HPV有关的宫颈损伤。 Tevogen Bio is advancing cell therapies to treat HPV-associated precancerous cervical lesions in women, using its investigational product TVGN 920. 这种治疗旨在消除HPV,防止经常损伤和潜在的子宫颈癌。 This therapy aims to eliminate HPV, preventing recurrent lesions and potential cervical cancer. Tevogen利用其ExacTell技术针对HPV基因组的具体领域。 Utilizing its ExacTcell technology, Tevogen targets specific areas of the HPV genome. 该公司的更广泛目标是提供个性化免疫疗法,以满足大量病人的大量保健需求。 The company's broader goal is to provide personalized immunotherapies for significant health needs in large patient populations.